Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Defined daily dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,752 result(s) found for: Defined daily dose. Displaying page 1 of 138.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-019466-81 Sponsor Protocol Number: LPA114255 Start Date*: 2016-12-12
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100 mg, GSK2190915 300 mg...
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002784-91 Sponsor Protocol Number: HAW0501 Start Date*: 2006-02-06
    Sponsor Name:Cardiff and Vale NHS Trust
    Full Title: A Randomized, Multicentre, Parallel Group Single-Blind Study to Assess the Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily versus Divided Doses Three Times Dai...
    Medical condition: Ulcerative colitis is characterized by acute and chronic inflammatory changes to the mucosa and submucosa of the colon and rectum. Clinical presentations include increased stool frequency, bloody d...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005110-41 Sponsor Protocol Number: 9999999999999999999 Start Date*: 2008-12-09
    Sponsor Name:not applicable
    Full Title: Circadian Influence on Renal Clearance of Aminoglycosides in cystic fibrosis patients
    Medical condition: Repeated or extended dosing of aminoglycosides may cause damage to the proximal tubuli, resulting in renal impairment. Renal impairment affects up to 40 % of adult CF patients, measured after estim...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013648-35 Sponsor Protocol Number: PENTA 18 Start Date*: 2010-06-23
    Sponsor Name:PENTA Foundation
    Full Title: KONCERT A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir...
    Medical condition: Paediatric HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    12 10021881 HIV-1 Infection SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) NL (Ongoing) FR (Completed) GB (Completed) ES (Completed) PT (Completed) BE (Completed) DE (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2005-004434-40 Sponsor Protocol Number: SCO104962 Start Date*: 2005-11-29
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treat...
    Medical condition: COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001098-26 Sponsor Protocol Number: MK-7264-034 Start Date*: 2018-09-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain
    Medical condition: Moderate to severe Endometriosis-related pain (ERP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10014788 Endometriosis related pain LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000627-24 Sponsor Protocol Number: 000134 Start Date*: 2014-06-26
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A follow-up study to examine the presence of anti-human growth hormone antibodies following a randomised, open-label, parallel-group, multi-centre trial (FE 999905 CS07) in which the efficacy and s...
    Medical condition: Idiopathic growth hormone deficiency
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002199-28 Sponsor Protocol Number: VFCr-12/2015 Start Date*: 2016-10-11
    Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel
    Full Title: Prospective, open-label, multicenter, multinational, randomized trial to investigate the non-inferiority of treatment with Vagisan® Moisturising Cream in comparison to an Estriol containing cream i...
    Medical condition: postmenopausal women suffering from symptoms of vulvovaginal dryness
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038604 - Reproductive system and breast disorders 10047791 Vulvovaginal dryness PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005293-22 Sponsor Protocol Number: D589GC00003 Start Date*: 2014-08-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80...
    Medical condition: Asthma
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000188-15 Sponsor Protocol Number: AL1402ac Start Date*: 2017-01-09
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter randomized double-blind placebo-controlled clinical trial for evaluation of efficacy and safety of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation o...
    Medical condition: allergic bronchial asthma and allergic rhinitis or rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10039097 Rhinoconjunctivitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed) LT (Completed) DE (Completed) ES (Completed) LV (Completed) AT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004419-31 Sponsor Protocol Number: B2C106093 Start Date*: 2006-03-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single a...
    Medical condition: Asthma and Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005032-34 Sponsor Protocol Number: MK-0991-058 Start Date*: 2015-02-27
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Sequential-Panel, Open-Label, Noncomparative Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Caspofungin Acetate in Neonates and Infants Less Than 3 Months of ...
    Medical condition: Empirical therapy for fungal infections
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002787-27 Sponsor Protocol Number: ACP-001_CT-004 Start Date*: 2013-02-11
    Sponsor Name:Ascendis Pharma A/S
    Full Title: A multicenter, Phase 2, randomized, open label, active-controlled, parallel-group study investigating the safety, tolerability, and efficacy of different dose levels of ACP-001 administered once we...
    Medical condition: Growth Hormone Deficiency (GHD) in pre-pubertal children
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) GR (Completed) BG (Completed) SI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004775-78 Sponsor Protocol Number: 1014802-203 Start Date*: 2016-05-09
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
    Medical condition: Neuropathic Pain From Lumbosacral Radiculopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014315 10054095 Neuropathic pain LLT
    20.0 10029205 - Nervous system disorders 10050219 Lumbar radiculopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GB (Completed) CZ (Completed) SK (Completed) AT (Completed) ES (Completed) NL (Completed) BE (Completed) FR (Completed) RO (Completed) BG (Completed) LT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004905-29 Sponsor Protocol Number: CCSJ117A12201C Start Date*: 2020-12-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled study to assess the efficacy and safety of CSJ117, when added to existing asthma therapy in patients ≥18 years of ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) PL (Prematurely Ended) BG (Prematurely Ended) FR (Completed) SK (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000031-59 Sponsor Protocol Number: TT-02 Start Date*: 2012-09-12
    Sponsor Name:ALK-Abelló A/S
    Full Title: A dose-response evaluation of ALK tree AIT
    Medical condition: Subjects with a documented clinically relevant history of moderate to severe birch pollen induced allergic rhinoconjunctivitis (with or without asthma) with symptoms despite having received symptom...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) NO (Completed) SE (Completed) NL (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-003668-29 Sponsor Protocol Number: DIUR-014 Start Date*: 2022-02-04
    Sponsor Name:Diurnal Limited
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study of Chronocort Compared with Immediate-Release Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over with Congenital ...
    Medical condition: Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005338-35 Sponsor Protocol Number: PM1111138 Start Date*: 2009-04-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 months, on in-vivo macrophage activity, as assessed by FDG-PET/CT im...
    Medical condition: GW-856553 is under development as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004488-30 Sponsor Protocol Number: TAPAS-PK-2014 Start Date*: 2014-01-31
    Sponsor Name:Haga Hospital
    Full Title: Targeting Antibiotics to Pseudomonas Aeruginosa in Small airways (TAPAS) study in patients with cystic fibrosis: pharmacokinetics (PK)
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000575-88 Sponsor Protocol Number: SHP647-305 Start Date*: 2019-02-28
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 305)
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 11:19:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA